公开(公告)号：US20230330184A1

公开(公告)日：2023-10-19

申请号：US18318492

申请日：2023-05-16

Applicant: Spectrum Pharmaceuticals Inc. ,  Hanmi Pharm Co., Ltd.

Inventor： Gajanan Bhat ,  Shanta Chawla ,  Jae Hyuk Choi ,  Eun jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC: A61K38/19 ,  C07K16/46 ,  A61K47/60

CPC classification number: A61K38/193 ,  C07K16/46 ,  A61K47/60 ,  C07K2317/53 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/522 ,  C07K2317/524

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

公开(公告)号：US11684655B2

公开(公告)日：2023-06-27

申请号：US16996635

申请日：2020-08-18

Applicant: Spectrum Pharmaceuticals, Inc. ,  Hanmi Pharm Co., Ltd.

Inventor： Gajanan Bhat ,  Shanta Chawla ,  Jae Hyuk Choi ,  Eun Jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC: A61K38/19 ,  A61K47/60 ,  C07K16/46

CPC classification number: A61K38/193 ,  A61K47/60 ,  C07K16/46 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

公开(公告)号：US20210008166A1

公开(公告)日：2021-01-14

申请号：US16996635

申请日：2020-08-18

Applicant: Spectrum Pharmaceuticals Inc.

Inventor： Gajanan Bhat ,  Lee Allen ,  Jae Hyuk Choi ,  Eun Jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC: A61K38/19 ,  A61K47/60 ,  C07K16/46

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

公开(公告)号：US20230270822A1

公开(公告)日：2023-08-31

申请号：US18181852

申请日：2023-03-10

Applicant: Spectrum Pharmaceuticals Inc. ,  Hanmi Pharmaceutical

Inventor： Gajanan Bhat ,  Shanta Chawla ,  Jae Hyuk Choi ,  Eun jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC: A61K38/19 ,  A61K47/60 ,  C07K16/46

CPC classification number: A61K38/193 ,  A61K47/60 ,  C07K16/46 ,  C07K2317/528 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.